Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United …
$0.91-7.64%
报价 2026-11-13
市值
$231.4M
EV
–
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -53.3%
$0.90$1.96
筛选结果
live estimateFilter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| LCTXLineage Cell Therapeutics, Inc. | $231.4M | -7.6% | – | – | – | – | – | |
| OMEROmeros Corporation | $1.27B | -2.8% | +5000.0% | 95.8% | 9.7x | 10.7x | – | |
| NGNENeurogene Inc. | $378.1M | +0.1% | -44.4% | 0% | – | – | – | |
| BNTCBenitec Biopharma Inc. | $315.4M | -0.6% | -13.8% | 0% | – | – | – | |
| AUTLAutolus Therapeutics plc | $311.4M | -1.7% | – | 15.7% | – | – | – | |
| FULCFulcrum Therapeutics, Inc. | $288M | +2.4% | -98.9% | 0% | – | – | – | |
| OCGNOcugen, Inc. | $280.9M | -5.2% | -5.4% | 88.5% | – | – | – | |
| GALTGalectin Therapeutics Inc. | $200.9M | -2.9% | +395.0% | 0% | – | – | – | |
| ADCTADC Therapeutics S.A. | $171.1M | -5.0% | – | 88.8% | – | – | – | |
| 同行中位数 | – | – | -9.6% | 7.8% | 9.7x | 10.7x | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。